Cargando…

Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Detalles Bibliográficos
Autores principales: Baraliakos, X, Listing, J, Brandt, J, Rudwaleit, M, Sieper, J, Braun, J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834029/
http://dx.doi.org/10.1186/ar1551
_version_ 1782178524024537088
author Baraliakos, X
Listing, J
Brandt, J
Rudwaleit, M
Sieper, J
Braun, J
author_facet Baraliakos, X
Listing, J
Brandt, J
Rudwaleit, M
Sieper, J
Braun, J
author_sort Baraliakos, X
collection PubMed
description
format Text
id pubmed-2834029
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28340292010-03-08 Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab Baraliakos, X Listing, J Brandt, J Rudwaleit, M Sieper, J Braun, J Arthritis Res Ther Poster Presentation BioMed Central 2005 2005-02-17 /pmc/articles/PMC2834029/ http://dx.doi.org/10.1186/ar1551 Text en Copyright ©2005 BioMed Central Ltd
spellingShingle Poster Presentation
Baraliakos, X
Listing, J
Brandt, J
Rudwaleit, M
Sieper, J
Braun, J
Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
title Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
title_full Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
title_fullStr Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
title_full_unstemmed Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
title_short Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
title_sort clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
topic Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834029/
http://dx.doi.org/10.1186/ar1551
work_keys_str_mv AT baraliakosx clinicalresponsetodiscontinuationofantitumornecrosisfactortherapyinpatientswithankylosingspondylitisafter3yearsofcontinuoustreatmentwithinfliximab
AT listingj clinicalresponsetodiscontinuationofantitumornecrosisfactortherapyinpatientswithankylosingspondylitisafter3yearsofcontinuoustreatmentwithinfliximab
AT brandtj clinicalresponsetodiscontinuationofantitumornecrosisfactortherapyinpatientswithankylosingspondylitisafter3yearsofcontinuoustreatmentwithinfliximab
AT rudwaleitm clinicalresponsetodiscontinuationofantitumornecrosisfactortherapyinpatientswithankylosingspondylitisafter3yearsofcontinuoustreatmentwithinfliximab
AT sieperj clinicalresponsetodiscontinuationofantitumornecrosisfactortherapyinpatientswithankylosingspondylitisafter3yearsofcontinuoustreatmentwithinfliximab
AT braunj clinicalresponsetodiscontinuationofantitumornecrosisfactortherapyinpatientswithankylosingspondylitisafter3yearsofcontinuoustreatmentwithinfliximab